Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Neutral
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9874.8761
Address
Suite 301 55 Lime Street Sydney, New South Wales (NSW) 2000
Description
CardieX Ltd. engages in the provision of designing, manufacturing, and marketing medical devices used in cardiovascular health management. It operates through the following geographical segments: Americas, Europe, and Asia Pacific. The Americas segment includes pharmaceutical trials business. The Europe segment focuses on the Middle East and Africa. The Asia Pacific segment is involved in the operations of Asia, Australia, and New Zealand. The company was founded by Ross Harricks, Niall Charles Edgar Cairns, Craig R. Cooper, and Michael Francis O'Rourke in 1994 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.17
Trade Value (12mth)
AU$5,370.00
1 week
-5.05%
1 month
-20%
YTD
16.05%
1 year
-22.18%
All time high
7.82
EPS 3 yr Growth
-36.70%
EBITDA Margin
-57.90%
Operating Cashflow
-$8m
Free Cash Flow Return
-359.30%
ROIC
-314.80%
Interest Coverage
-5.30
Quick Ratio
1.00
Shares on Issue (Fully Dilluted)
192m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
18 December 24 |
Cardiex Completes Placement Ahead of CONNEQT US Launch
×
Cardiex Completes Placement Ahead of CONNEQT US Launch |
18 December 24 |
Proposed issue of securities - CDX
×
Proposed issue of securities - CDX |
16 December 24 |
Trading Halt
×
Trading Halt |
04 December 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 December 24 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
02 December 24 |
Appendix 3Y x2
×
Appendix 3Y x2 |
29 November 24 |
Cardiex AGM Executive Update
×
Cardiex AGM Executive Update |
29 November 24 |
Results of Meeting
×
Results of Meeting |
29 November 24 |
Proposed issue of securities - CDX
×
Proposed issue of securities - CDX |
01 November 24 |
CONNEQT Pulse Pre-orders Commence
×
CONNEQT Pulse Pre-orders Commence |
31 October 24 |
September Quarterly Appendix 4C
×
September Quarterly Appendix 4C |
31 October 24 |
September Quarterly Activities Report
×
September Quarterly Activities Report |
29 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
08 October 24 |
Change in substantial holding
×
Change in substantial holding |
30 September 24 |
2024 Annual Report
×
2024 Annual Report |
30 September 24 |
2024 Appendix 4G and Corporate Governance Statement
×
2024 Appendix 4G and Corporate Governance Statement |
30 August 24 |
Appendix 4E
×
Appendix 4E |
06 August 24 |
Corporate Webinar Presentation
×
Corporate Webinar Presentation |
01 August 24 |
Cardiex Corporate Update Webinar
×
Cardiex Corporate Update Webinar |
31 July 24 |
June Quarterly Appendix 4C
×
June Quarterly Appendix 4C |
31 July 24 |
June Quarterly Activities Report
×
June Quarterly Activities Report |
26 June 24 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
18 June 24 |
Cardiex Sales and Operations Update
×
Cardiex Sales and Operations Update |
17 June 24 |
Options Prospectus
×
Options Prospectus |
17 June 24 |
Proposed issue of securities - CDX
×
Proposed issue of securities - CDX |
03 June 24 |
Results of June 2024 Extraordinary General Meeting
×
Results of June 2024 Extraordinary General Meeting |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.